Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Navidea Biopharmaceuticals, Inc.

< Previous 1 2 Next >
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB OTC
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB OTC
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB OTC
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB OTC
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Files Appeal in CRG Case
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Tickers NAVB
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.